Chuang Hsin-Ni, Pei Wen, Kuo Tzong-Fu, Liu Yu-Hao, Wang Chia-Yih, Chang Yen-Wei, Chuang Chi-Hsuan, Yang Chang-Huan, Chuang Ming-Hsi
Ph.D. Program of Management, Chung Hua University, Hsinchu, Taiwan.
College of Management, Chung Hua University, Hsinchu, Taiwan.
Front Pharmacol. 2025 Mar 12;16:1409056. doi: 10.3389/fphar.2025.1409056. eCollection 2025.
Acute kidney injury (AKI) is a major and unmet medical need, characterized by a sudden onset of kidney dysfunction that often occurs within 7 days. Adipose-derived stem cells (ADSCs) are known for their regenerative, differentiative, and repair abilities, making them a promising therapeutic option for kidney injury. Platelet-rich fibrin releasate (PRFr), derived from platelet-rich fibrin after static incubation, contains numerous growth factors that may promote the differentiation and proliferation of stem cells. Additionally, acupoints such as Shenshu (BL23) have been used in clinical practice and experimental settings, particularly in renal failure treatments.
This study aimed to evaluate the synergistic effects of ADSCs and PRFr, administered separately or in combination, at the Shenshu acupoint (BL23) in New Zealand white rabbits with acute kidney injury. The treatment groups were injected with ADSCs, PRFr, or a combination of both. Serum creatinine (CRE) and blood urea nitrogen (BUN) levels were measured to assess kidney function. Additionally, histological examination of kidney tissue was performed to observe morphological changes and tissue repair.
The PRFr + ADSCs treatment group exhibited a significant reduction in CRE and BUN levels during the second week following transplantation. After 7 weeks of treatment, the PRFr + ADSCs group showed the most favorable kidney repair outcomes, with intact glomeruli, no edema or vacuole-like changes in the renal tubular epithelial cells, and no significant infiltration of inflammatory cells in the surrounding tissues.
The administration of PRFr, ADSCs, and their combination at the Shenshu acupoint (BL23) demonstrated a potential therapeutic effect in repairing damaged renal cells, improving kidney function, and reducing serum CRE and BUN levels. These findings suggest that injection of PRFr, ADSCs, and their combination at the Shenshu acupoint (BL23) can effectively repair damaged renal cells and improve kidney function in AKI. The observed synergistic effect indicates that this approach holds potential as a novel therapeutic strategy for kidney injury. Further research is needed to optimize treatment protocols and elucidate the underlying mechanisms.
急性肾损伤（AKI）是一项重大且尚未满足的医疗需求，其特征为肾功能突然出现障碍，通常在7天内发生。脂肪来源干细胞（ADSCs）以其再生、分化和修复能力而闻名，使其成为肾损伤治疗的一个有前景的选择。富含血小板纤维蛋白释放物（PRFr）是在静态孵育后从富含血小板纤维蛋白中获得的，含有许多可能促进干细胞分化和增殖的生长因子。此外，诸如肾俞穴（BL23）等穴位已应用于临床实践和实验环境中，尤其是在肾衰竭治疗方面。
本研究旨在评估在患有急性肾损伤的新西兰白兔的肾俞穴（BL23）单独或联合给予ADSCs和PRFr的协同作用。治疗组分别注射ADSCs、PRFr或两者的组合。测量血清肌酐（CRE）和血尿素氮（BUN）水平以评估肾功能。此外，对肾组织进行组织学检查以观察形态变化和组织修复情况。
PRFr + ADSCs治疗组在移植后的第二周，CRE和BUN水平显著降低。治疗7周后，PRFr + ADSCs组显示出最有利的肾脏修复结果，肾小球完整，肾小管上皮细胞无水肿或空泡样变化，周围组织无明显炎症细胞浸润。
在肾俞穴（BL23）给予PRFr、ADSCs及其组合显示出在修复受损肾细胞、改善肾功能以及降低血清CRE和BUN水平方面具有潜在的治疗效果。这些发现表明，在肾俞穴（BL23）注射PRFr、ADSCs及其组合可有效修复急性肾损伤中受损的肾细胞并改善肾功能。观察到的协同作用表明这种方法作为肾损伤的一种新型治疗策略具有潜力。需要进一步研究以优化治疗方案并阐明潜在机制。
